Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249360 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHRSMN1; SMN2ANPEP | |
| SCHEMBL14192720 | 0.80 | KMT2A (0.34) | ALDH1A1TSHRSMN1; SMN2ANPEP | |
| SCHEMBL1752393 | 0.80 | TSHR (0.37) | ALDH1A1TSHRSMN1; SMN2ANPEP | |
| SCHEMBL11670845 | 0.77 | CA1 (0.38) | ALDH1A1TSHRSMN1; SMN2ANPEP | |
| SCHEMBL16006403 | 0.77 | TDP1 (0.33) | SMN1; SMN2ANPEP | |
| SCHEMBL23175627 | 0.76 | GAA (0.45) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL13315130 | 0.76 | CA1 (0.32) | SMN1; SMN2 | |
| SCHEMBL15268831 | 0.75 | — | — | |
| SCHEMBL16866506 | 0.75 | — | — | |
| SCHEMBL7039726 | 0.74 | CA1 (0.33) | ALDH1A1TSHRSMN1; SMN2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | ALDH1A1 1901/4885TSHR 134/4885CTSL 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.